F-star Therapeutics (F-star Therapeutics) Interest Coverage : 0 (At Loss) (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. F-star Therapeutics's Operating Income for the three months ended in Sep. 2022 was $-13.71 Mil. F-star Therapeutics's Interest Expense for the three months ended in Sep. 2022 was $-0.38 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for F-star Therapeutics's Interest Coverage or its related term are showing as below:

FSTX's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

F-star Therapeutics Interest Coverage Historical Data

The historical data trend for F-star Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

F-star Therapeutics Interest Coverage Chart

F-star Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Interest Coverage

N/A

F-star Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Interest Coverage	Get a 7-Day Free Trial							-	13.43	-	-	-

Competitive Comparison of F-star Therapeutics's Interest Coverage

For the Biotechnology subindustry, F-star Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

F-star Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where F-star Therapeutics's Interest Coverage falls into.

F-star Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

F-star Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2021 is calculated as

Here, for the fiscal year that ended in Dec. 2021, F-star Therapeutics's Interest Expense was $-0.84 Mil. Its Operating Income was $-30.71 Mil. And its Long-Term Debt & Capital Lease Obligation was $12.33 Mil.

F-star Therapeutics did not have earnings to cover the interest expense.

F-star Therapeutics's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Here, for the three months ended in Sep. 2022, F-star Therapeutics's Interest Expense was $-0.38 Mil. Its Operating Income was $-13.71 Mil. And its Long-Term Debt & Capital Lease Obligation was $10.54 Mil.

F-star Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

F-star Therapeutics (NAS:FSTX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

F-star Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

F-star Therapeutics (F-star Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT

Website

https://www.f-star.com

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

Executives

Geoffrey Race	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks	officer: See Remarks	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster	director, officer: PRESIDENT AND CEO	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham	director	890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire	officer: CHIEF MEDICAL OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis	officer: CHIEF SCIENTIFIC OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein	director	35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik	director	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow	officer: General Counsel and Secretary	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani	officer: VP of Finance and Treasurer	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon	director, 10 percent owner	86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116